Plain-English translation of NCT06110130 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether empagliflozin, a medication originally developed for diabetes, can help protect the kidneys of people with chronic kidney disease who do not have diabetes. The study focuses on African American veterans because this group is disproportionately affected by kidney disease, and researchers want to understand whether this medication might help prevent further kidney damage.
Current ways of measuring kidney damage don't always show improvement quickly, even when a treatment is working. This study is looking for better ways to detect early signs of kidney injury, and wants to learn whether this medication might be beneficial for people without diabetes who have chronic kidney disease.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to take either the medication empagliflozin or a placebo (a pill with no active ingredient) once daily for several months. During the study, you would have regular visits to the VA Medical Center where doctors would check your blood pressure, kidney function, and collect urine samples to measure how your kidneys are responding to the treatment.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States